Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. The company also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane, a daratumumab biosimilar targeting CD38 for the treatment of multiple myeloma. The company has a strategic partnership with JOINN Biologics US Inc. to provide customized development services for Xdarzane, Xbrane´s biosimilar candidate referencing Darzalex. The company was incorporated in 2008 and is headquartered in Solna, Sweden.
Frequently asked questions
What sector does Xbrane Biopharma AB (XBRANE) operate in?
Xbrane Biopharma AB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Xbrane Biopharma AB (XBRANE) current stock price?
As of the latest data, Xbrane Biopharma AB stock price is SEK 12.40, with a previous close of SEK 12.00. Xbrane Biopharma AB gained SEK 0.40 in the last trading session, representing a 3.33% increase.
What is Xbrane Biopharma AB (XBRANE) current market capitalization?
Xbrane Biopharma AB market cap is approximately 255.51 million.
What is Xbrane Biopharma AB (XBRANE) Earnings Per Share (EPS)?
The trailing EPS is -SEK 3.28, and the forward EPS is -SEK 0.01.
What is Xbrane Biopharma AB (XBRANE) EBITDA?
Xbrane Biopharma AB EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -11.98 million.
Does Xbrane Biopharma AB (XBRANE) pay dividends?
No. Xbrane Biopharma AB does not pay a dividend.
What is Xbrane Biopharma AB (XBRANE) beta (volatility) score?
Xbrane Biopharma AB has a beta of 0.775, indicating lower volatility than the overall market.
